Home » Stocks » PainReform

PainReform Ltd. (PRFX)

Stock Price: $5.37 USD -0.15 (-2.72%)
Updated Sep 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 47.85M
Revenue (ttm) n/a
Net Income (ttm) -1.28M
Shares Out 8.91M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 21, 2020
Last Price $5.37
Previous Close $5.52
Change ($) -0.15
Change (%) -2.72%
Day's Open 5.50
Day's Range 5.30 - 5.50
Day's Volume 32,597
52-Week Range 5.23 - 7.85

More Stats

Market Cap 47.85M
Enterprise Value 53.07M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 8.91M
Float 3.24M
EPS (basic) n/a
EPS (diluted) -0.15
FCF / Share -1.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -689,000
Net Income -1.28M
Free Cash Flow -609,000
Net Cash -5.23M
Net Cash / Share -0.59
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -69.18%
ROE n/a
ROIC -30.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-0.69-0.50
Net Income-1.28-0.83
Shares Outstanding0.580.58
Earnings Per Share-4.17-3.24
Operating Cash Flow-0.61-0.64
Free Cash Flow-0.61-0.64
Cash & Equivalents0.950.05
Total Debt6.174.52
Net Cash / Debt-5.23-4.47
Book Value-12.24-11.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PainReform Ltd.
Country Israel
Employees 3
CEO Eli Hazum

Stock Information

Ticker Symbol PRFX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: PRFX
IPO Date September 1, 2020


PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.